Contrasting cardiovascular risk profiles and prescribed cardio-protective therapies in newly-diagnosed type 2 diabetes identified through screening and standard practice
| Autor: | Kamlesh Khunti, David R. Webb, Melanie J. Davies, Laura J. Gray, H. Dallosso, Sandra Campbell |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
medicine.medical_specialty Cardiotonic Agents endocrine system diseases Endocrinology Diabetes and Metabolism Type 2 diabetes Disease Newly diagnosed Risk profile Endocrinology Risk Factors Diabetes mellitus Internal medicine Internal Medicine Medicine Humans Mass Screening Stage (cooking) Mass screening Antihypertensive Agents Aged Dyslipidemias Hypolipidemic Agents business.industry nutritional and metabolic diseases Type 2 Diabetes Mellitus General Medicine Middle Aged medicine.disease Diabetes Mellitus Type 2 Cardiovascular Diseases Hyperglycemia Hypertension Physical therapy business |
| Zdroj: | Diabetes research and clinical practice. 91(3) |
| ISSN: | 1872-8227 |
| Popis: | Screening for Type 2 diabetes mellitus (T2DM) may improve long-term outcomes by managing cardiovascular risk at an earlier stage of the disease. The cardiovascular risk profile of screen-detected (SD) T2DM is ill defined and has not been compared to conventional newly diagnosed (CD) cases.Baseline data from SD (n=337) and CD (n=824) cohorts were compared. SD adopted mixed approaches to screening, population based (n=214) and cardiovascular-risk factor targeted (n=123). CD reflected UK primary care practice with cases referred within four weeks of diagnosis.People with SD T2DM were leaner, had a lower HbA1c(%) and lower triglyceride but were more hypertensive compared to people with CD T2DM. Fewer SD were on blood pressure lowering (46% vs. 60%, p0.0001), statin (30% vs. 41%, p0.0001) or anti-platelet (15% vs. 27%, p0.0001) therapies. Modelled 10 year cardiovascular disease (CVD) risk was actually greater in the SD group compared to CD (CVD: 20.8 vs. 17.2, p=0.0001).Individuals with SD T2DM are at high risk of CVD as a result of untreated hyperglycaemia, hypertension and dyslipidaemia. Those prescribed antihypertensive or lipid-lowering therapies frequently still had inadequate control. Identifying vascular risk by screening for latent glucose disease provides therapeutic opportunities for earlier intervention. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect